Citations

Clear

1417 citation(s) found for "Li, Simon".

Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA ® ) administered by colonoscopy for prevention of recurrent Clostridioides difficile infectio
Khanna, Sahil , Yoho, David, Handel, Daniel Van, Clark, Brian J., Awad, Tahany , Guthmueller, Beth, Armandi, Daniel, Knapple, W , Safdar, Nasia , Baggott, Brian, Simon, Karen, Knapple, Whitfield , Feuerstadt, Paul , Feuerstadt, Paul

Mayo Clinic

Therapeutic Advances in Gastroenterology | April 23, 2025 | Volume: 18 | Issue: No issue available | Pages: No page available

10.1177/17562848251339697 | PMID 40321366 Get It

Background: Recurrent Clostridioides difficile infection (rCDI) occurs in up to 35% of patients with CDI, and further recurrence is common. Fecal microbiota, live-jslm (RBL) is safe and effective for preventing rCDI in adults following antibiotic treatment for rCDI when administered rectally. There is clinical interest in alternative routes of administration. Objectives: CDI-SCOPE assessed the safety and clinical effectiveness of RBL when administered via colonoscopy to adults with rCDI. Design: Single-arm, exploratory phase IIIb trial conducted at 12 sites in the United States. Methods: Eligible adults with rCDI received one administration of RBL consisting of one 150-mL dose of RBL, delivered via colonoscopy to the right side of the colon. The primary endpoint assessed RBL-related treatment-emergent adverse events (TEAEs) within 8 weeks of RBL administration or until confirmed treatment failure. Secondary endpoints included treatment success (absence of CDI recurrence for 8 weeks following RBL administration), physician experience administering RBL via colonoscopy, and physician perception of participant benefit. Results: Of 54 participants screened, 41 were enrolled and received RBL via colonoscopy; 39 participants completed the 8-week visit. Five TEAEs in four participants (9.8%) were assessed as related to RBL, all of which were gastrointestinal and mild in severity. Overall, 18 participants (43.9%) experienced 33 TEAEs within 8 weeks, most of which were of mild (25/33; 75.8%) or moderate (5/33; 15.2%) severity. No TEAEs led to intensive care unit admission or death. Overall, 39 participants (95.1%) experienced treatment success; 2 participants (4.9%) withdrew consent and had an indeterminate outcome. Among physicians, 90.2% of investigators indicated a “positive” or “very positive” experience administering RBL by colonoscopy. All physicians assessed participant benefit as “much” or “very much” improved. Conclusion: This single-arm study suggests RBL administered via colonoscopy is practical, safe, and effective for preventing CDI recurrence following antibiotic treatment in adults. Trial registration: ClinicalTrials.gov: NCT05831189.
Abstract 4935: Disentangling the association between age and overall survival in an international cohort of patients with advanced prostate cancer
Sodipo, Michelle O. , Siefkas, Anna , Sauer, Christopher M. , Dogo, Hassan, Waihenya, Charles, Hotte, Sebastién J. , Cathomas, Richard , Enting, Deborah , Khoo, Vincent , Ogo, Chidiebere, McKay, Rana R. , Fischer, Stefanie , Chatwal, Monica , McDermott, Raymond, Davis, Ian D. , Ragin, Camille , Anderson, Simon , Cannon, Laurel, Chan-Cuzydlo, Alyssa, Grant, Marie, Gerke, Travis , George, Daniel J. , Mucci, Lorelei A. , Anderson, Simon G , Hotte, Sebastien J , Guard, Hannah E. , McGrath, Colleen B. , Howard, Lauren E. , Stopsack, Konrad H. , Dreicer, Robert , Esteban, Emilio , Popoola, Ademola , Bjartell, Anders , N., Kim , Tagawa, Scott T. , Ong, Michael M. , Kolinsky, Michael Paul , Mateo, Joaquı́n , Cheng, Heather H. , Szmulewitz, Russell Z , Whang, Young E. , Sharma, Anand , Pouliot, Frédéric , Crabb, Simon J. , Climent, Miguel A., McDermott, Raymond, Badal, Simone , GREAVES, NATALIE S. , Autio, Karen A. , Cannon, Laurel, McManus, Hannah D. , Kantoff, Philip W.

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 4935-4935

10.1158/1538-7445.am2025-4935 Get It

Abstract Introduction: Most people who die from prostate cancer are older than 75 years. However, prostate cancer diagnosed at younger ages is often more aggressive. While epidemiologic studies have examined the association between age and survival in patients with prostate cancer overall, the clinical drivers of this relationship in patients with advanced disease remain unclear. We leveraged the International Registry of Men with Advanced Prostate Cancer (IRONMAN, NCT03151629) to (1) quantify the association between age and overall survival and (2) explore whether this association is explained by treatments. Methods: We included 3, 734 patients enrolled from 15 countries with new diagnoses of metastatic hormone sensitive (mHSPC, N=2, 642) or castration resistant prostate cancer (CRPC, N=1, 092). Age at enrollment was categorized as <55, 55-59, 60-64 (reference), 65-69, 70-74, 75-79, 80-84, 85+ years. We computed age-specific death rates (95% confidence intervals [CIs]) by disease state (mHSPC, CRPC) at enrollment. To explore whether this relationship was explained by treatment, we fitted disease state-stratified Cox models and sequentially adjusted for (1) de novo metastatic status and country, and (2) baseline treatment (androgen deprivation therapy [ADT] alone, ADT + androgen receptor pathway inhibitors [ARPI], ADT + chemotherapy, ADT + ARPI + chemotherapy, other). Results: Over 5.5 years of follow-up (median: 3.2 years, IQR: 1.7, 4.8), 995 patients died from any cause. Younger patients were more likely to have de novo metastatic disease. Among those with mHSPC at enrollment, the age-specific death rates per 1, 000 person-years followed a J-shaped pattern: 80 (95% CI: 54, 117) in patients under 55 years, 58 (46, 74) in patients aged 60-64, 102 (78, 133) in patients aged 80-84, and 172 (125, 236) in patients aged 85 and older. The death rates among those with CRPC followed a similar pattern, albeit rates were higher in magnitude: 212 (95% CI: 140, 323) in patients under 55 years, 153 (115, 202) in patients aged 60-64, 200 (155, 258) in patients aged 80-84, and 204 (142, 291) in patients aged 85 and older. After adjusting for disease state, country, and the timing of diagnosis of metastases, death rates were substantially higher for ages 75-79 (HR 1.4; 95% CI 1.1, 1.7), 80-84 years (HR 1.6; 95% CI 1.2, 2.1), and 85 years and older (HR 2.0; 95% CI: 1.5, 2.7) compared to ages 60-64 years. Patients aged under 55 years had 1.4-fold higher death rates (95% CI: 1.0, 1.9) compared to those 60-64 years. After additionally adjusting for baseline treatment, overall survival remained worse for the older patients and the youngest age group with hazard ratios remaining meaningfully unchanged. Conclusion: Age at enrollment is associated with overall survival in people with advanced prostate cancer enrolled in IRONMAN in a J-shaped pattern. This relationship is not explained by differences in baseline treatment. Citation Format: Hannah E. Guard, Michelle O. Sodipo, Colleen B. McGrath, Anna Siefkas, Lauren E. Howard, Konrad H. Stopsack, Christopher M. Sauer, Robert Dreicer, Emilio Esteban, Hassan M. Dogo, Ademola Popoola, Charles Waihenya, Anders Bjartell, Kim N. Chi, Sebastien Hotte, Richard Cathomas, Deborah Enting, Scott Tagawa, Michael Ong, Michael Kolinsky, Vincent Khoo, Joaquin Mateo, Chidiebere N. Ogo, Rana R. McKay, Stefanie Fischer, Heather H. Cheng, Russell Szmulewitz, Young E. Whang, Anand Sharma, Frédéric Pouliot, Simon Crabb, Monica S. Chatwal, Miguel A. Climent, Raymond McDermott, Ian D. Davis, Camille Ragin, Folakemi T. Odedina, Simon Anderson, Simone Badal, Natalie Greaves, Karen A. Autio, Laurel Cannon, Alyssa Chan-Cuzydlo, Marie Grant, Travis Gerke, Hannah D. McManus, Philip W. Kantoff, Daniel J. George, Lorelei A. Mucci, IRONMAN investigator team. Disentangling the association between age and overall survival in an international cohort of patients with advanced prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 4935.
Abstract 7415: Association between sleep traits and risk of non-Hodgkin's lymphoma subtypes: a mendelian randomization study in the International Lymphoma Epidemiology (InterLymph) Consortium
Shah, Pankhil, Crawford, Brittany, Macauda, Angelica , Hildebrandt, Michelle A.T., Caporaso, Neil E., Yeager, Meredith, Dean, Michael , Goldin, Lynn R. , Camp, Nicola J. , Casabonne, Delphine , Nieters, Alexandra, Chanock, Stephen J., Machiela, Mitchell J., Conry, Michael , Cheah, Simon , Brown, Elizabeth E. , Vachon, Celine M. , Berndt, Sonja I. , McKay, James , Hjalgrim, Henrik, Sucheston‐Campbell, Lara, Machiela, Mitchell J. , Machiela, Mitchell J , Merchant, Anwar T. , Birmann, Brenda M. , Hildebrandt, Michelle A.T. , Norman, Aaron D. , Yeager, Meredith , Vivo, Immaculata De , Waller, Rosalie G. , Canzian, Federico , Unal, Pelin, Ziv, Elad , Marinac, Catherine R. , Nieters, Alexandra , Chanock, Stephen Jacob , Zhong, Charlie , Park, Hanla A. , Hofmann, Jonathan N. , Vachon, Celine M. , Slager, Susan L. , Wang, Sophia , Vijai, Joseph , Smith-Byrne, Karl , Clay‐Gilmour, Alyssa

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 7415-7415

10.1158/1538-7445.am2025-7415 Get It

Abstract Introduction: With over 80, 000 new cases of non-Hodgkin's lymphoma (NHL) diagnosed annually, modifiable risk factors remain unclear. Circadian disruption, linked to cancers like breast and prostate, affects immune cells (e.g., natural killer cells and T-helper cells) by altering their trafficking and proliferation. Some studies (PMID: 30566672, 27611440) suggest long sleep may increase overall NHL risk, including a Mendelian randomization (MR) study (PMID: 32895918). However, no research has examined the causal relationship between sleep traits, including long sleep, and NHL risk, by subtypes. We hypothesize that sleep traits are causally associated with NHL subtypes in European populations, testing this using MR with data from the International Lymphoma Epidemiology Consortium (InterLymph). Methods: We conducted two-sample MR using genome-wide association studies (GWAS) summary data for sleep traits and NHL subtypes. Only independent, genome-wide significant (p < 5×10-8) Single Nucleotide Polymorphisms (SNPs) were selected as valid instruments, sourced from the UK Biobank. Sleep traits included chronotype (153 SNPs), insomnia (48 SNPs), sleep duration (78 SNPs), excessive daytime sleepiness (37 SNPs), short sleep (27 SNPs), and long sleep (8 SNPs). NHL subtype data were from InterLymph: follicular lymphoma (6, 508 cases / 64, 183 controls), mantle cell lymphoma (1, 169 cases / 61, 603 controls), Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL: 1, 697 cases / 59, 333 controls), and chronic lymphocytic leukemia (8, 522 cases / 67, 653 controls). The primary analysis used inverse-variance weighted (IVW) random-effects, with MR-Egger for pleiotropy adjustment. Results: Using the IVW method, we did not identify any statistically significant causal association between sleep traits and the risk of NHL subtypes, but did yield several intriguing trends. Long sleep (sleep duration >= 9 h per night) showed a marginally increased NHL risk [Odds ratio (OR) range: 1.51 - 247.9] across each subtype. Short sleep (sleep duration < 7 h per night) showed a similar trend [OR range: 1.25 - 1.81], except for WM/LPL, where we noticed a negative trend. The confidence limit for long sleep was imprecise due to the small number of variants. We did not notice any significant directional horizontal pleiotropy or weak instrument bias. Conclusions: We found no conclusive evidence of a relationship between sleep traits and four NHL subtypes. However, we see suggestive trends of long and short sleep associated with higher risk of some NHL subtypes. These findings align with the previous studies, which showed long sleep was associated with higher risk of NHL overall. Future directions include expanding our analysis to additional NHL subtypes, generating polygenic risk scores, and conducting stratified analyses. Citation Format: Pankhil Shah, Brittany Crawford, Anwar Merchant, Brenda Birmann, Angelica Macauda, Michelle A. Hildebrandt, Aaron Norman, Neil E. Caporaso, Meredith Yeager, Michael Dean, Immaculata De Vivo, Lynn Goldin, Nicola J. Camp, Rosalie Griffin, Delphine Casabonne, Federico Canzian, Pelin Unal, Elad Ziv, Catherine R. Marinac, Alexandra Nieters, Stephen J. Chanock, Mitchell J. Machiela, Michael Conry, Charlie Zhong, Hanla A. Park, Simon Cheah, Jonathan N. Hofmann, Elizabeth E. Brown, Celine Vachon, Susan Slager, Sonja Berndt, Sophia S. Wang, Vijai Joseph, James McKay, Henrik Hjalgrim, Lara Sucheston-Campbell, Karl Smith-Byrne, Alyssa Clay-Gilmour. Association between sleep traits and risk of non-Hodgkin's lymphoma subtypes: a mendelian randomization study in the International Lymphoma Epidemiology (InterLymph) Consortium [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 7415.
Abstract 3630: First-line therapies and subjective cognitive function trajectories among international metastatic hormone-sensitive prostate cancer survivors
Sodipo, Michelle O. , Siefkas, Anna , Drecier, Robert, Dogo, Hassan, Waihenya, Charles, Hotte, Sebastién J. , Cathomas, Richard , Enting, Deborah , Heath, Elisabeth I. , McKay, Rana R. , Fischer, Stefanie, Chatwal, Monica , McDermott, Raymond, Davis, Ian D. , Ragin, Camille, Anderson, Simon , Harrison, Sharon , Cannon, Laurel, Grant, Marie, Chan-Cuzydlo, Alyssa, Gerke, Travis , George, Daniel, Haneuse, Sebastien , Mucci, Lorelei A. , Registry, on behalf of the IRONMAN, Anderson, Simon G , Hotte, Sebastien J , Morgans, Alicia K. , Warner, Erica T. , Rencsok, Emily M. , Howard, Lauren E. , McGrath, Colleen B. , Stopsack, Konrad H. , Sauer, Christopher Martin , Esteban, Emilio , Popoola, Ademola , Bjartell, Anders , N., Kim , Tagawa, Scott T. , Ong, Michael M. , Lorente, David , Cheng, Heather H. , Whang, Young E. , Pouliot, Frédéric , Crabb, Simon J. , Climent, Miguel A., McDermott, Raymond, Ragin, Camille , GREAVES, NATALIE S. , Badal, Simone , Autio, Karen A. , McManus, Hannah D. , Kantoff, Philip W. , Registry, on behalf of the IRONMAN

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 3630-3630

10.1158/1538-7445.am2025-3630 Get It

Abstract Introduction: The standard of care for metastatic hormone-sensitive prostate cancer (mHSPC) has evolved with the expanded approval of androgen receptor pathway inhibitors (ARPIs) alongside androgen deprivation therapy (ADT). ADT alone has been shown to affect cognitive function. However, the cognitive impact of distinct treatment combinations remains unclear. We investigated the association between first-line systemic treatments and the trajectory of subjective cognitive function among mHSPC survivors in the International Registry for Men with Advanced Prostate Cancer (IRONMAN). Methods: This analysis included 2435 newly diagnosed mHSPC patients enrolled across 15 countries between July 2017 and August 2024. Treatments were reported by site personnel and physicians. For this analysis, we focused on first-line systemic treatment and classified treatment groups at enrollment as ADT monotherapy (referent), ADT + ARPIs, or ADT + chemotherapy. Subjective cognitive function was assessed via the EORTC QLQ-C30 Cognitive Function subscale, with patient-reported scores (range 0-100) collected at enrollment and every 3 months for up to 5 years; higher scores reflect better cognitive function. Associations were estimated using linear mixed effects models with clustering by study site and country to examine differences at enrollment and across trajectories of subjective cognitive function by first-line treatment, adjusting for demographic and clinical factors. Results: Median age at enrollment was 70 years, with a median follow-up of 1.7 years. 724 (30%) participants were treated with ADT monotherapy, 1317 (54%) with ADT + ARPIs, and 394 (16%) with ADT + chemotherapy. Mean cognitive function scores at enrollment were 85.4 (Standard Deviation [SD] 19.5) for participants treated with ADT monotherapy, 86.7 (SD 17.3) for ADT + ARPIs, and 86.7 (SD 18.0) for ADT + chemotherapy. Cognitive function scores decreased by -0.60 points (95% Confidence Interval [CI] -0.72, -0.48) per year among those treated with ADT monotherapy, with similar rates observed for those treated with ADT + chemotherapy. Participants treated with ADT + ARPIs had a slower decline in cognitive function, with scores decreasing by -0.36 points (95% CI -0.60, -0.08) per year. Conclusion: In this international cohort of mHSPC survivors, subjective cognitive function scores were generally high at enrollment but declined over time. There was no evidence of worse cognitive function in those treated with ADT + ARPIs nor ADT + chemotherapy over time compared to ADT monotherapy. Cognitive functioning is a key component of survivorship, and defining cognitive trajectories associated with first-line treatment can inform supportive interventions, patient treatment decision-making, and clinical guidelines. Citation Format: Michelle O. Sodipo, Alicia K. Morgans, Erica T. Warner, Emily M. Rencsok, Lauren E. Howard, Colleen B. McGrath, Anna Siefkas, Konrad H. Stopsack, Christopher Sauer, Robert Drecier, Emilio Esteban, Hassan M. Dogo, Ademola Popoola, Charles Waihenya, Anders Bjartell, Kim Chi, Sebastien Hotte, Richard Cathomas, Deborah Enting, Scott Tagawa, Michael Ong, David Lorente, Elisabeth Heath, Rana McKay, Stefanie Fischer, Heather H. Cheng, Young E. Whang, Frederic Pouliot, Simon Crabb, Monica Chatwal, Miguel A. Climent, Raymond McDermott, Ian D. Davis, Camille Ragin, Folakemi Odedina, Natalie Greaves, Simone Badal, Simon Anderson, Sharon Harrison, Karen Autio, Laurel Cannon, Marie Grant, Alyssa Chan-Cuzydlo, Travis Gerke, Hannah D. McManus, Philip W. Kantoff, Daniel George, Sebastien Haneuse, Lorelei A. Mucci, on behalf of the IRONMAN Registry. First-line therapies and subjective cognitive function trajectories among international metastatic hormone-sensitive prostate cancer survivors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 3630.
Permissive central tolerance plus defective peripheral checkpoints license pathogenic memory B cells in CASPR2-antibody encephalitis
Sun, Bo , Fernandes, Dominique , Soltys, John , Paneva, Sofija , Harrison, Ruby , Harrison, Anna, Makuch, Mateusz , Fichtner, Miriam L. , Donat, Robert F. , Akdeniz, Deniz, Bayuangga, Halwan Fuad , Im, Min Gyu , Williams, Robyn , VASCONCELOS, ANA RAQUEL GOUVEIA , Thomsen, Selina, Fower, Andrew , Sun, Ruyue, Fox, Hannah , Mgbachi, Victor , Davies, Alexander J. , Tseng, Mandy , Handel, Adam E. , Kelly, Mark , Zhao, Meng , Bancroft, James , Bashford-Rogers, Rachael , Pluvinage, John V. , Dandekar, Ravi , Alvarenga, Bonny D. , Dustin, Lynn B. , Rinaldi, Simon , Owens, Raymond J. , Anthony, Daniel C. , Bennett, David , Davis, Simon J. , Wilson, Michael R. , O’Connor, Kevin C. , Carvalho, Ana Luı́sa , Irani, Sarosh R. , Kienzler, Anne-Kathrin , Paneva, Sofija , Harrison, Ruby , Harrison, Anna L , Fichtner, Miriam L , Bayuangga, Halwan , Im, Min Gyu , Vasconcelos, Ana , Fower, Andrew , Fox, Hannah , Davies, Alexander , Tseng, Mandy , Handel, Adam , Kelly, Mark , Zhao, Meng , Bancroft, James , Pluvinage, John V , Dandekar, Ravi , Alvarenga, Bonny D , Dustin, Lynn B , Rinaldi, Simon , Owens, Ray , Anthony, Daniel , Bennett, David L , Davis, Simon J , Wilson, Michael R , O'Connor, Kevin C , Carvalho, Ana Luisa , Irani, Sarosh R , Sun, Bo , Williams, Robyn L , Ramanathan, Sudarshini , Sun, Ruyue, Waters, Patrick

Mayo Clinic

Science Advances | April 16, 2025 | Volume: 11 | Issue: 16 | Pages: No page available

10.1126/sciadv.adr9986 | PMID 40238887 Get It

Autoantibody-mediated diseases targeting one autoantigen provide a unique opportunity to comprehensively understand the development of disease-causing B cells and autoantibodies. Convention suggests that such autoreactivities are generated during germinal center reactions. Here, we explore earlier immune checkpoints, focusing on patients with contactin-associated protein-like 2 (CASPR2)–autoantibody encephalitis. In both disease and health, high (~0.5%) frequencies of unmutated CASPR2-reactive naïve B cells were identified. By contrast, CASPR2-reactive memory B cells were exclusive to patients, and their B cell receptors demonstrated affinity-enhancing somatic mutations with pathogenic effects in neuronal cultures and mice. The unmutated, precursor memory B cell receptors showed a distinctive balance between strong CASPR2 reactivity and very limited binding across the remaining human proteome. Our results identify permissive central tolerance, defective peripheral tolerance, and autoantigen-specific tolerance thresholds in humans as sequential steps that license CASPR2-directed pathology. By leveraging the basic immunobiology, we rationally direct tolerance-restoring approaches, with an experimental paradigm applicable across autoimmunity.
Implementation outcomes of a patient decision-aid in a diverse population with systemic lupus erythematosus in 15 US rheumatology clinics
Singh, Jasvinder A. , Eisen, Seth A. , Chatham, Winn, Narain, Sonali , Kamen, Diane L. , Trotter, Kimberly , Majithia, Vikas , Ching, Cathy Lee , Aouhab, Zineb , Venuturupalli, Swamy, McMahon, Maureen , Bhairavarasu, Kalpana, Beasley, Mark , Kamen, Diane L, Charleston, Majithia, Vikas, Jackson, Venuturupalli, Swamy, McMahon, Maureen, Lim, S Sam, Bhairavarasu, Kalpana, Eisen, Seth , Narain, Sonali , Kamen, Diane L , Trotter, Kimberly , Majithia, Vikas , Lee Ching, Cathy , Ramsey-Goldman, Rosalind , Kim, Alfred H J , McMahon, Maureen , Lim, S Sam , Meara, Alexa Simon , Singh, Jasvinder A , Hearld, Larry R. , Annapureddy, Narender , Venuturupalli, Swamy, Wallace, Daniel J , Ramsey‐Goldman, Rosalind , Kim, Alfred H.J. , Lim, S. Sam , Bhairavarasu, Kalpana, Kalunian, Kenneth , Beasley, Timothy Mark , Kamen, Diane L, Charleston, Majithia, Vikas, Venuturupalli, Swamy, McMahon, Maureen, Lim, S Sam, Bhairavarasu, Kalpana

Mayo Clinic

Rheumatology | April 13, 2025 | Volume: 64 | Issue: 8 | Pages: 4631-4640

10.1093/rheumatology/keaf205 | PMID 40221856 Get It

Abstract Objective The objective of this study was to examine the clinical outcomes during the implementation of a self-administered patient decision-aid (PtDA) for lupus. Methods We provided an effective computerized lupus PtDA in 15 rheumatology outpatient clinics 2019–2024 (including the COVID pandemic). We undertook Organizational Readiness to Implement Change Surveys (ORICs) and Team Learning and Psychological Safety Surveys (TLPSSs) at baseline. The primary study outcome objective measure, percent penetration/reach, was defined as the number of patients who viewed the lupus PtDA at the end of the study, divided by the total number of eligible patients (times 100). We used validated clinical personnel surveys to examine the perceived lupus PtDA appropriateness, acceptability, feasibility, success, and permanence, at 4 months, 12 months and 24 months post-PtDA implementation. Results Among the sites, the clinical personnels’ (n = 184) baseline ORIC commitment and efficacy scores (a 0–5 scale, higher = better) ranged from 3.5 to 4.2, and 3.4 to 4.4, respectively; the TLPSS scores (a 0–7 scale, higher = better) were 3.9–5.5 for internal learning, 3.7–5.6 for external learning, and 4.3–5.5 for psychological safety. The penetration (primary outcome) among 15 geographically diverse US rheumatology clinics ranged from 3% to 44%. We found that the total number of providers in the clinic was positively associated with higher penetration. Clinical personnel–perceived lupus PtDA outcomes were optimal at 4 months (all scale scores ranged from 1 to 5, higher = better): (i) appropriateness, 3.43 (s.d. 0.86); (ii) acceptability, 3.53 (s.d. 0.83); (iii) feasibility, 3.44 (s.d. 0.71); (iv) success, 3.41 (s.d. 0.73); and (v) permanence, 3.22 (s.d. 0.74). Conclusion We implemented a lupus PtDA with varied success rates during the COVID pandemic; more providers were associated with higher clinic penetration. Clinical personnel perceived high lupus PtDA appropriateness, acceptability, feasibility, success, and permanence that persisted up to 24 months. Trial Registration ClinicalTrials.gov, http://clinicaltrials.gov, NCT03735238.
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements
Nakazawa, Seshiru , Pecci, Federica , Odintsov, Igor , Gazgalis, Dimitris , Gottlieb, Felix H. , Ricciuti, Biagio , Zullo, Lodovica , Alessi, Joao V. , Federico, Alessandro Di , Aldea, Mihaela , Garbo, Edoardo , Saini, Arushi , Jiang, Jie , Baldacci, Simon , Makarem, Maisam , Locquet, Marie-Anaïs , Haradon, Danielle , Italiano, Antoîne , Lavaud, Pernelle , Vasseur, Damien , Planchard, David , Watanabe, Y., Mahran, Hoda A., Niu, Jiaxin , Swan, Leong Swan, Tay, Kevin , Kizilbash, Sani H. , Yu, Kin-Hung P. , Zhang, Xiaoling , Chen, Pan , Sangem, Mythili, Che, Jianwei , Sholl, Lynette M. , Jänne, Pasi A. , Di Federico, Alessandro , Gandhi, Malini M , Saini, Arushi , Feng, William W , Jiang, Jie , Baldacci, Simon , Facchinetti, Francesco , Makarem, Maisam , Locquet, Marie-Anaïs , Haratani, Koji , Haradon, Danielle , Besse, Benjamin , Italiano, Antoine , Remon, Jordi , Lavaud, Pernelle , Vasseur, Damien , Planchard, David , Sato, Yusuke , Watanabe, Yukako , Owen, Scott , Cortot, Alexis B , Mahran, Hoda , Forster, Martin D , Niu, Jiaxin , Tomasini, Pascale , Leong, Swan Swan , Tay, Kevin , Esteban, Emilio , Minchom, Anna , Kizilbash, Sani H , Cruz-Correa, Marcia , Yu, Kin-Hung Peony , Zhang, Xiaoling , Chen, Pan , Sangem, Mythili , Che, Jianwei , Sholl, Lynette , Jänne, Pasi A , Awad, Mark M , Odintsov, Igor , Ricciuti, Biagio , Aldea, Mihaela , Garbo, Edoardo , Gazgalis, Dimitris , Besse, Benjamin , Cortot, Alexis B. , Tomasini, Pascale , Cruz‐Correa, Marcia , Awad, Mark M.

Mayo Clinic

Cancer Discovery | April 9, 2025 | Volume: 15 | Issue: 6 | Pages: 1129-1140

10.1158/2159-8290.cd-24-1726 | PMID 40202082 Get It

Abstract Oncogenic translocations involving the MET gene have been reported in several cancer types, but detailed clinicogenomic characterization of these cancers is not well defined. In addition, prospective clinical trials evaluating the antitumor activity of MET inhibitors in MET rearrangement–positive cancers are limited. In this study, in a pan-cancer analysis of >46,000 solid tumors with comprehensive genomic profiling, we identified oncogenic MET rearrangements in ∼0.04% of cancers. Preliminary analysis from a phase II clinical trial of the type I MET tyrosine kinase inhibitor (TKI) vebreltinib in MET fusion–positive solid tumors demonstrated an objective response rate of 50% and disease control rate of 79%, with antitumor activity seen in diverse cancer types, including lung adenocarcinoma and intrahepatic cholangiocarcinoma, among others. Similar to MET exon 14–altered lung cancer, secondary mutations in the kinase domain can confer resistance to MET TKIs in MET fusion–positive cancers. Overall, these data categorize MET rearrangements as actionable targets in solid tumors. Significance: MET rearrangement–positive cancers are not well-characterized, and optimal treatment strategies are yet to be defined. Through comprehensive genomic analysis, preclinical modeling, and preliminary results of a phase II clinical trial, we demonstrate that MET fusions are a unique molecular subtype of cancers targetable with vebreltinib, a TKI in development.
EP4.5 Safety of Intra-articular Corticosteroid Hip Injections: A Retrospective Analysis of Avascular Necrosis Development
Simon, Karissa, Scott, Parker, Sellon, Jacob L. , Johnson, Adam, Clark, Sean C. , Pan, Xuankang , Boettcher, Brennan J. , Johnson, Adam, Hevesi, Mario

Mayo Clinic

Journal of Hip Preservation Surgery | April 2, 2025 | Volume: 12 | Issue: Supplement_1 | Pages: i80-i80

10.1093/jhps/hnaf011.258 Get It

Abstract Background: Intra-articular corticosteroid injections (ICSI) have been shown to be an effective symptomatic non-operative treatment for hip osteoarthritis (OA) and other joint-related pain. There has been recent dispute over the true risk of complications from ICSI specifically when injected into the hip. Avascular necrosis (AVN) of the femoral head has been reported to occur in up to 30.5% of patients after undergoing hip ICSI, and up to 50.6% of patients experiencing osteoarthritis progression in as little as 3 months following injection. Purpose: To analyze the current protocol of hip ICSIs performed by two fellowship-trained non-operative sports medicine physicians and assess the rate of femoral head avascular necrosis. We hypothesized that the rate of AVN will be less than what has been recently reported in the literature. Study Design: Retrospective chart review Methods: Patients that underwent at least one intra-articular corticosteroid hip injection by two fellowship trained non-operative sports medicine physicians at this institution were identified using an institutional database. Exclusion criteria included injections with contrast dye used for imaging, injections that administered orthobiologics to the intra-articular, and non-intra-articular injections. Procedure notes were reviewed for anesthetic and steroid type, dosage, and needle size. Each chart was screened for demographic information, post-injection infections, AVN diagnosis, and subsequent hip replacement. 10 patients were identified with an AVN diagnosis. Their MRNs were sent to a board-certified radiologist at the same medical institution. The radiologist was blinded to the patient’s chart and instructed to identify the first radiograph with evidence of AVN. Patients were excluded if the reviewer did not agree with the diagnosis as it appeared in the medical chart or the AVN developed post-traumatically. Results: 449 patients, 530 hips, underwent 1.8 ± 1.4 ICSIs and 16.3% underwent THA at an average of 2.2 ± 2.3 years following their first injection. Of the 530 hips that underwent ICSI, only 1 hip demonstrated findings of AVN on radiographs following the first injection, and this patient had been taking oral prednisone for over 20 years. Conclusions: Intra-articular corticosteroid injections are a relatively safe symptomatic treatment option for hip pain secondary to both OA and non-OA pathology to be considered when other non-operative treatment options have failed. While the use of steroids comes with an inherent risk of osteonecrosis and cartilage damage, these results demonstrate that, when performed properly with ultrasound guidance and sterile technique, the risk of femoral head avascular necrosis is minimal.
EP6.37 Outcomes of Arthroscopic Versus Open Iliopsoas Fractional Lengthening after Total Hip Arthroplasty
Holliday, Charles L. , Simon, Karissa, Levy, Bruce A. , Taunton, Michael J. , Hevesi, Mario

Mayo Clinic

Journal of Hip Preservation Surgery | March 30, 2025 | Volume: 12 | Issue: Supplement_1 | Pages: i101-i101

10.1093/jhps/hnaf011.326 Get It

Abstract Background: Iliopsoas (IP) tendinitis is a recognized complication following total hip arthroplasty (THA) and isolated iliopsoas fractional lengthening (IPFL) has been able to provide symptom relief. IPFL has traditionally been done openly; however, the arthroscopic IPFL has recently been described as an alternative, offering the potential for lower surgical site morbidity and a more favorable post-operative recovery. Purpose: To compare clinical and patient reported outcomes following open and arthroscopic IPFL. We hypothesize that patients undergoing arthroscopic IPFL will have improved pain, function, and satisfaction with lower post-operative complication rates when compared to patients undergoing open IPFL. Methods: Patients with symptomatic IP tendinitis following THA who underwent IPFL from 1988-2023 were reviewed. Inclusion criteria included 2 years follow-up and no concomitant procedures. Patient records were evaluated for surgery type, radiographic anterior acetabular component overhang, reoperations, and need for revision THA. Surveys were used to report overall surgery satisfaction, postoperative subjective hip flexion strength and anterior groin pain improvement, mHHS, SANE score, Tegner activity scale, and VAS for pain. Results: Fifty-two patients (16 males and 36 females, age: 63.9 ± 11.7 years, BMI: 28.8 ± 5.4 kg/m2) were followed for a mean of 68.7 (24.0 – 203.7) months postoperatively. Overall surgery satisfaction was 7.9 (arthroscopic) and 6.0 (open) (p = 0.178). 86% of patients treated arthroscopically reported feeling “slightly” or “much better” and 86% also reported improvement in their anterior groin pain, compared to 55% and 45% respectively treated openly. In the arthroscopic cohort, 64% reported that their hip flexion strength was “slightly ” or “much better”, compared to 36% treated openly. Average VAS pain score was 1.7 ± 2.7 at rest (arthroscopic: 1.1 ± 2.2, open: 3.3 ± 3.2, p = 0.0092) and 3.0 ± 1.3 (arthroscopic: 3.1 ± 1.3, open: 2.6 ± 1.1) with use. Mean postoperative Tegner score was 3.0 ± 1.3 (arthroscopic: 3.1 ± 1.3, open: 2.6 ± 1.1) compared to 2.3 ± 1.2 preoperatively (arthroscopic: 2.3 ± 1.3, open: 2.1 ± 1.1) (p = 0.0018). Mean post-operative mHHS and SANE score was 74.9 ± 21.6 (arthroscopic: 77.0 ± 19.0, open: 69.2 ± 26.9) and 69.7± 29.7 (arthroscopic: 70.9 ± 28.7, open: 66.7 ± 31.8) respectively. Conclusion: The results indicate that arthroscopic IPFL trends towards significantly improved pain, function, and satisfaction scores when compared to patients undergoing open IPFL, and should be considered when appropriate over an open IPFL given the less invasive nature of an arthroscopic procedure.
EP3.18 Arthroscopic Iliopsoas Fractional Lengthening after THA Results in Improved PROs and Low Rates of Revision THA: A Multicenter Study
Simon, Karissa, Vogel, Michael , Levy, Bruce A. , Nho, Shane, Jurgensmeier, Kevin , Taunton, Michael J. , Nho, Shane J. , Hevesi, Mario

Mayo Clinic

Journal of Hip Preservation Surgery | March 30, 2025 | Volume: 12 | Issue: Supplement_1 | Pages: i75-i75

10.1093/jhps/hnaf011.239 Get It

Abstract Purpose: 1) To report the clinical outcomes and reoperation rates of arthro- and endo-scopic iliopsoas release at short-term follow-up following ipsilateral total hip arthroplasty from two separate medical institutions, and 2) to evaluate whether demographic and radiographic parameters are associated with postoperative patient reported outcomes. Methods: Patients with iliopsoas tendinitis in the setting of prior THA that underwent arthroscopic iliopsoas fractional lengthening from 1988 – 2023 were reviewed at two academic institutions. Patients were included if they had minimum 12-month follow-up and were evaluated for preoperative anterior acetabular component overhang, surgery satisfaction, postoperative subjective hip flexion strength and anterior groin pain improvement, modified Harris Hip Score (mHHS), Single Assessment Numeric Evaluation (SANE) score, Tegner activity scale, visual analog scale (VAS), and revision hip arthroplasty. Results: Sixty hips in 58 patients (19 males, 39 females) were followed for a mean of 39.3 (12.0-105.9) months postoperatively. 77% of patients reported feeling “much” or “slightly better”, 75% reported improved anterior groin pain, and 60% reported improved subjective hip flexion strength. Surgery satisfaction was 7.2 ± 3.3 (scale of 0 to 10). Mean postoperative mHHS, VAS pain at rest, VAS pain with use, and SANE scores were 73.9 ± 19.4, 1.3 ± 2.4, 3.8 ± 2.9, and 71.9 ± 21.9 respectively. Preoperative anterior acetabular component overhang was 3.3 ± 6.5 mm and didn’t significantly correlate with postoperative PROs (p ≥ 0.45). Tegner score improved to 2.9 ± 1.4 from 2.5 ± 1.7 preoperatively (p = 0.0253). Three patients underwent revision arthroplasty at a mean of 25.3 (11.6 – 40.4) months postoperatively, with an acetabular component revision rate of 3.3%. Conclusions: Satisfactory outcomes and low revision arthroplasty rates were observed in patients undergoing arthroscopic iliopsoas lengthening following THA. There was no statistically significant relationship between anterior acetabular component overhang and final PROs. Level of Evidence: IV; Retrospective Case Series